Client news

A&O Shearman advises on Mineralys Therapeutics’ upsized USD287.5 million follow-on equity offering

A&O Shearman advises on Mineralys Therapeutics’ upsized USD287.5 million follow-on equity offering
Published Date
Sep 9 2025
Related people
Image of Ilir Mujalovic
Ilir MujalovicPartner, New York
Image of Harald Halbhuber
Harald HalbhuberPartner, New York
Image of Ekaterina Bogdanov
Ekaterina BogdanovAssociate, Toronto
Image of Kazumasa Watanabe
Kazumasa WatanabeAssociate, New York
image of Colin Cantwell
Colin CantwellAssociate, New York
Image of Austin Grossfeld
Austin GrossfeldAssociate, New York
Image of Jennifer Morton
Jennifer MortonPartner, New York
Image of Taylor Pugliese
Taylor PuglieseAssociate, New York
Image of Dominic Petric
Dominic PetricAssociate, New York
Image of Lorenz Haselberger
Lorenz HaselbergerPartner, New York
A&O Shearman advised the underwriters in Mineralys Therapeutics, Inc.’s upsized USD287.5m follow-on equity offering. Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease, obstructive sleep apnea, and other diseases driven by dysregulated aldosterone.

“We are delighted to have been part of this successful transaction which further reflects A&O Shearman’s strength and expertise in healthcare equity capital markets” said Ilir Mujalovic, the global co-head of U.S. capital markets and global ECM. 

The A&O Shearman team was led by U.S. capital markets partners Ilir Mujalovic and Harald Halbhuber, with key support from Katya Bogdanov, Kaz Watanabe, and Colin Cantwell.

IP transactional partner JB Betker and associate Austin Grossfeld provided advice on intellectual property matters. Financial services regulatory partner Jennifer Morton and associates Taylor Pugliese and Dominic Petric provided advice on financial services regulatory matters. Tax partner Lorenz Haselberger and associate Ryan Sedwick provided tax advice.

Related capabilities